

2019 Pitch Presenters

Session 1

	Affiliation	Name of Speaker	Title
1	 SkySea Pharmaceutical Inc.	Yuji Kogami	Drug Discovery of Oxytocin related Autism Spectrum Disorder
	2006 AsahiKasei Pharmaceutical 2006-2010 PRISM BioLab Corporation Director 2010- D.D.P. Corporation, CEO & President 2015- SkySea Pharmaceutical Inc., CEO & President		
2	 ReguGene Co., Ltd.	Shuji Ikeda	Epigenetic Drug Discovery by Gene Switch
	Ph.D. Managing Director of ReguGene Co., Ltd. and researcher at Chemistry Department, Graduate School of Kyoto University after working as assistant professor and researcher at university, national research institute, and venture company in Singapore.		
3	 Cellagility Biomed Pvt. Co.	Kouichi Hasegawa	Enabling Cell Therapy – From India to world –
	Junior Associate Prof. Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University, and Scientific Advisory board, Cellagility Biomed, India. Previously served as a faculty in University of Southern California, University of Melbourne and inStem, India, and a SAB at Cell Guidance System (UK) and Stem Cell Innovation (Japan).		
4	 iBody Inc.	Teruyo Kato	Robust screening of monoclonal antibodies from rabbits and humans
	Graduate school of Nagoya University/R&D section at food material company/Researcher of Project at Knowledge Hub Aichi/JSPS PD Research fellowship/CEO at iBody		
5	 ERISA Co., LTD.	Yoshiyuki NOTSU	Companion Diagnostic “AI Program” that enables successful development of therapeutic drugs for Alzheimer’s diseases
	After completion of master’s degree of Graduate School of Agricultural and Life Sciences, the University of Tokyo, engaged in general management for overseas subsidiaries and domestic business development for Japanese research reagents manufacture. After 13 years’ employment, joined two life science start-ups as management. Since October 2017, current position.		
6	 Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology	Tadashi Kimura	Disulfide-Rich Peptides, promising scaffolds for pharmaceuticals, agrichemicals and cosmetics.
	Dr. Kimura received Ph.D. from Tsukuba University. He has deep experiences on ion-channel and tarantula venom peptides research. He is a visiting associate professor at united graduate school of drug discovery and medical information science, Gifu University.		
7	 School of Dentistry, Health Sciences University of Hokkaido	Takashi Saito	Dentin regeneration therapy using Laminin-derived peptide, Laminin-411 and 511
	The speaker engaged in the research on tooth remineralization and regeneration in UNC Dental Research Center in the United States and AIST in Japan, and then since 2003, has been performing the research on the development of novel therapy for deep dental caries in Health Sciences University of Hokkaido.		
8	 Tongue Lab	Jean Michel Mauclair	Paradigm changing curative treatment for sleep apnea.
	1991 French Certified Public Accountant, Paris -France 1983-1984 Deloitte & Touche -International audit firm, 1989-1995 Lafarge Group- CFO in a subsidiary, 1996-2000 Lindsey Technologies-Paris,France,Denver,USA:Information Technology start up, CFO 1998-2008 CPA PC- Paris France: Merger and Acquisitions 2002-2011 BioQuanta Corp – Aurora, Co, USA - Paris France :Biotechnology start up: co-founder, CEO. 2012-2016 Management consultant: Growth and technology start-up companies (France, Mexico) 2012 Tongue Lab – London UK - Paris France: founder, Chairman & CEO. 2017 Tongue Lab Japan Office		
9	 Elcyo Co., Ltd.	Giichi Shibuya	New solution for eye correction “full-range tunable eyeglasses”
	After graduation from Keio University, Shibuya started working at TDK corp. for 30 years since 1984. At Osaka University He has been focusing on the research of Fresnel liquid crystal lens since 2014, and launched Elcyo Co., Ltd. in 2019.		